Residency · Residency · Neurology

Intracerebral Hemorrhage: Acute Management and Prognosis

Overview

Intracerebral hemorrhage accounts for 10 to 15% of all strokes yet carries the highest mortality of any stroke subtype, with approximately 40% of patients dying within 30 days. Acute management centers on blood pressure control, reversal of coagulopathy, prevention of hematoma expansion, and avoidance of secondary brain injury. Surgical intervention remains controversial for most supratentorial ICH, though recent trials of minimally invasive techniques have begun to shift the landscape. A particularly important and often underappreciated concern is the self-fulfilling prophecy of early withdrawal of care, which may worsen outcomes and confound prognostic data.

Etiology and Risk Factors

Hypertension is the most common cause and characteristically produces hemorrhages in the basal ganglia (putamen), thalamus, pons, and cerebellum. Cerebral amyloid angiopathy causes lobar hemorrhages predominantly in the elderly and is associated with recurrent bleeding, cortical superficial siderosis, and microbleeds visible on susceptibility-weighted imaging. Anticoagulation-related hemorrhages, whether from warfarin, DOACs, or heparin, carry a higher risk of expansion and worse outcomes. Vascular malformations such as AVMs, cavernous malformations, and dural arteriovenous fistulae should be considered particularly in young patients or when hemorrhage occurs in an atypical location. Other causes include hemorrhagic transformation of ischemic stroke, coagulopathies such as thrombocytopenia and DIC, illicit drug use (cocaine and amphetamines produce vasospasm and hypertensive surges), and tumor-related hemorrhage from metastases (melanoma, renal cell, choriocarcinoma) or primary brain tumors.

Initial Assessment

Imaging

Non-contrast CT head is the gold standard for rapid detection, revealing a hyperdense lesion with surrounding edema. CTA with a spot sign, indicating contrast extravasation within the hematoma, predicts ongoing expansion and identifies patients at high risk for growth. CT venography should be obtained if venous sinus thrombosis is suspected. MRI with SWI or GRE sequences detects microbleeds and can distinguish a CAA pattern from a hypertensive pattern, as well as identify underlying structural lesions, though it is not urgently required in the acute phase. Conventional angiography should be considered when a vascular malformation is suspected, particularly in young patients with lobar hemorrhage and no history of hypertension.

ICH Volume Estimation

The ABC/2 method provides a rapid bedside volume estimate: the largest diameter on CT (A) is multiplied by the perpendicular diameter (B) and by the number of CT slices containing hemorrhage times the slice thickness (C), then divided by 2. A volume exceeding 30 mL in supratentorial ICH is associated with poor prognosis. Hematoma expansion, defined as a greater than 33% increase or growth of more than 6 mL, occurs in approximately 30% of patients within the first 24 hours and is one of the most important determinants of outcome.

Blood Pressure Management

INTERACT2 Trial (2013)

INTERACT2 compared intensive blood pressure lowering (target SBP below 140 mmHg within one hour) to guideline-recommended management (SBP below 180 mmHg). While there was no significant difference in the primary outcome of death or major disability, the ordinal mRS analysis showed a favorable shift with intensive lowering, and the approach was demonstrated to be safe without increased neurological deterioration.

ATACH-2 Trial (2016)

ATACH-2 tested a more aggressive target (SBP 110-139 mmHg within 2 hours) against a standard range (SBP 140-179 mmHg). There was no benefit from this more intensive approach, and a trend toward increased renal adverse events suggested a floor below which aggressive lowering may cause harm.

Current Recommendations

The target SBP is 130 to 150 mmHg, with treatment initiated promptly within 2 hours of presentation. SBP below 130 mmHg should be avoided because of the risk of perihematomal ischemia. Preferred agents include IV nicardipine (which is easily titratable), IV labetalol, and IV clevidipine. Rapid, large blood pressure swings should be avoided; continuous infusion is preferable to bolus dosing.

Reversal of Anticoagulation

Warfarin-Associated ICH

Four-factor prothrombin complex concentrate (Kcentra) is first-line therapy, rapidly correcting the INR with dosing based on INR and weight. IV vitamin K 10 mg should always be administered concurrently because the PCC effect is transient while vitamin K provides sustained correction. Fresh frozen plasma is inferior to PCC due to slower onset, risk of volume overload, and incomplete correction, and should be used only if PCC is unavailable. The target is an INR below 1.3 as rapidly as possible, ideally within 1 to 2 hours.

DOAC-Associated ICH

For dabigatran, idarucizumab (Praxbind) 5 g IV is the specific reversal agent, achieving full reversal within minutes. For factor Xa inhibitors (apixaban, rivaroxaban, edoxaban), andexanet alfa (Andexxa) is the specific reversal agent given as a bolus plus infusion; it is effective but costly. Four-factor PCC at 50 IU/kg is a reasonable alternative when specific reversal agents are unavailable. Activated charcoal may be considered if the DOAC was ingested within 2 to 4 hours.

Heparin-Associated ICH

Protamine sulfate is given at 1 mg per 100 units of heparin administered in the preceding 2 to 3 hours, up to a maximum of 50 mg.

Thrombocytopenia or Antiplatelet-Associated ICH

Platelet transfusion is indicated for thrombocytopenia-associated ICH with a target above 100,000. However, the PATCH trial demonstrated that platelet transfusion for antiplatelet-associated ICH was harmful, so routine platelet transfusion should not be performed in this setting. Desmopressin (DDAVP) at 0.3 mcg/kg may improve platelet function in antiplatelet-associated ICH, though evidence is limited.

Surgical Management

STICH Trial (2005)

STICH compared early surgery to initial conservative treatment for spontaneous supratentorial ICH and found no overall benefit for early surgery. A subgroup analysis suggested that superficial lobar hemorrhages within 1 cm of the cortical surface might benefit.

STICH II Trial (2013)

STICH II focused specifically on superficial lobar ICH (within 1 cm of the cortical surface, volumes 10-100 mL) but again found no significant benefit for early surgery versus conservative management, though there was a trend toward benefit in patients who clinically deteriorated.

MISTIE III Trial (2019)

MISTIE III evaluated minimally invasive surgery with thrombolysis, using catheter-based clot aspiration with alteplase irrigation. The trial was negative for its primary endpoint overall, but a post-hoc analysis found that achieving a residual clot volume under 15 mL was associated with significantly better functional outcomes.

ENRICH Trial (2024)

ENRICH is the first positive surgical randomized controlled trial for supratentorial ICH. It evaluated minimally invasive parafascicular surgery for lobar ICH of 30 to 80 mL and demonstrated significant benefit for early minimally invasive surgery compared to medical management. This paradigm-shifting result supports early, minimally invasive evacuation for selected lobar hemorrhages.

Cerebellar Hemorrhage

Surgical evacuation is generally recommended when the hematoma exceeds 3 cm in diameter, when there is brainstem compression or hydrocephalus, or when neurological deterioration is occurring. Cerebellar ICH meeting these criteria is a neurosurgical emergency, and early suboccipital craniectomy can be life-saving.

Intraventricular Hemorrhage (IVH)

Intraventricular extension occurs in approximately 40% of ICH cases and is an independent predictor of poor outcome. An external ventricular drain is placed for obstructive hydrocephalus. The CLEAR III trial showed that intraventricular alteplase administered via EVD reduced mortality but did not improve functional outcomes.

Prognostic Scores and the Self-Fulfilling Prophecy

ICH Score

The ICH Score incorporates GCS, ICH volume, the presence of IVH, infratentorial origin, and age 80 or above. Scores range from 0 to 6, with a score of 4 or higher associated with greater than 90% 30-day mortality. Although widely used, the score has significant limitations.

The Self-Fulfilling Prophecy Problem

Early prognostication in ICH often leads to early withdrawal of care, which then ensures the predicted poor outcome. Studies have shown that withdrawal of life-sustaining treatment is the proximate cause of death in 40 to 70% of ICH fatalities. Patients who survive aggressive early care frequently achieve better-than-predicted outcomes. The AHA/ASA guidelines recommend delaying new withdrawal of care orders for at least 48 hours after ICH onset and caution against using prognostic scores as the sole basis for limiting treatment. Implicit biases related to age, race, and socioeconomic status may further influence prognostication and withdrawal decisions.

Medical Management Checklist

Patients should be admitted to an ICU or dedicated stroke unit with neuromonitoring capability. Frequent neurological assessments (every 1-2 hours initially) are essential. Blood pressure should be managed to a target SBP of 130-150 mmHg, and any coagulopathy should be reversed. Routine seizure prophylaxis is not recommended, but continuous EEG should be obtained if there is concern for subclinical seizures, and clinical seizures should be treated. DVT prophylaxis with intermittent pneumatic compression should begin immediately, and pharmacologic prophylaxis with LMWH or UFH can be started at 24-48 hours if the hematoma is stable. Glucose should be managed to avoid hyperglycemia (target 140-180 mg/dL), and fever should be treated aggressively given its association with worse outcomes. Hypotonic fluids should be avoided due to the risk of cerebral edema, and the head of the bed should be elevated to 30 degrees.

<image>A non-contrast CT head series showing different ICH locations and their most common etiologies: (1) putaminal hemorrhage (hypertensive), (2) thalamic hemorrhage (hypertensive), (3) lobar hemorrhage (cerebral amyloid angiopathy), (4) pontine hemorrhage (hypertensive), and (5) cerebellar hemorrhage (hypertensive). Each image is annotated with surrounding anatomy and clinical features. An adjacent MRI SWI sequence shows the difference between deep microbleed pattern (hypertensive) and cortical-subcortical microbleed pattern (CAA).</image>

<image>A treatment algorithm for anticoagulation reversal in ICH. The flowchart branches by anticoagulant type: (1) Warfarin -> 4-factor PCC (dose by INR) + IV vitamin K 10 mg, target INR <1.3 in <2 hours; (2) Dabigatran -> idarucizumab 5 g IV; (3) Factor Xa inhibitors -> andexanet alfa (bolus + infusion) or 4-factor PCC 50 IU/kg if unavailable; (4) Heparin -> protamine sulfate; (5) Antiplatelet-associated -> do NOT transfuse platelets (PATCH trial), consider DDAVP. Each branch includes dosing, expected time to reversal, and key caveats.</image>

<image>An infographic summarizing the major ICH surgical trials with their results. STICH (2005): overall negative; STICH II (2013): negative for lobar ICH; MISTIE III (2019): negative overall but residual clot <15 mL associated with benefit; ENRICH (2024): positive for minimally invasive surgery in lobar ICH 30-80 mL. Each trial is shown with a brief graphic of the surgical approach (craniotomy, catheter-based aspiration, parafascicular MIPS) and the primary outcome result. A concluding box highlights the shift toward minimally invasive techniques.</image>

Clinical Pearls

Hematoma expansion is the most important modifiable predictor of poor outcome, making rapid blood pressure control and coagulopathy reversal the primary acute interventions. The CTA spot sign, indicating contrast extravasation, identifies patients at high risk for hematoma expansion. The blood pressure target should be SBP 130 to 150 mmHg, avoiding both extremes: too high risks expansion, and too low risks perihematomal ischemia. Platelet transfusion should not be given for antiplatelet-associated ICH, as the PATCH trial demonstrated harm. ENRICH is the first positive surgical RCT for supratentorial ICH, supporting early minimally invasive evacuation for lobar hemorrhages of 30 to 80 mL. Cerebellar hemorrhage exceeding 3 cm with brainstem compression is a neurosurgical emergency that should not be delayed. The self-fulfilling prophecy of early withdrawal of care is a major confounder in ICH prognosis, and AHA/ASA guidelines recommend delaying new withdrawal orders for at least 48 hours.

References

• Anderson CS, et al. Rapid blood-pressure lowering in patients with acute intracerebral haemorrhage (INTERACT2). Lancet. 2013;381(9890):2033-2044.
• Qureshi AI, et al. Intensive blood-pressure lowering in cerebral hemorrhage (ATACH-2). N Engl J Med. 2016;375(11):1033-1043.
• Mendelow AD, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas (STICH). Lancet. 2005;365(9457):387-397.
• Hanley DF, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III). Lancet. 2019;393(10175):1021-1032.
• Pradilla G, et al. Trial of early minimally invasive removal of intracerebral hemorrhage (ENRICH). N Engl J Med. 2024;390(14):1277-1289.
• Hemphill JC, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032-2060.

Read this lecture as Markdown